Aprea Therapeutics, Inc. (APRE)
0.8052
+0.16
(+25.75%)
USD |
NASDAQ |
Aug 24, 16:00
0.765
-0.04
(-4.99%)
After-Hours: 07:22
Aprea Therapeutics Gross Profit Margin (Quarterly)
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2025 | -63.64% |
| September 30, 2025 | -200.0% |
| June 30, 2025 | 95.43% |
| March 31, 2025 | 96.62% |
| December 31, 2024 | 97.38% |
| September 30, 2024 | 98.48% |
| Date | Value |
|---|---|
| June 30, 2024 | 99.06% |
| March 31, 2024 | 98.37% |
| December 31, 2023 | 64.54% |
| September 30, 2023 | 0.00% |
| June 30, 2023 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Zymeworks, Inc. | 57.43% |
| Rhythm Pharmaceuticals, Inc. | 87.39% |
| Onconetix, Inc. | 25.15% |
| ACADIA Pharmaceuticals, Inc. | 90.81% |
| Alnylam Pharmaceuticals, Inc. | 76.88% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -50.87% |
| Return on Assets | -44.60% |
| Return on Invested Capital | -50.87% |
| Return on Net Operating Assets | -19.59K% |